{"article_title": "U.K. Health Service Panel Rejects Roche Cancer Drug on Price Grounds", "article_keywords": ["service", "cancer", "rejects", "price", "drug", "roche", "pressure", "women", "health", "rejected", "uk", "promising", "grounds", "reflects", "panel"], "article_url": "http://www.wsj.com/articles/u-k-health-service-panel-rejects-roche-cancer-drug-on-price-grounds-1407497976", "article_text": "LONDON\u2014One of Roche Holding AG's most promising new drugs\u2014for women with an aggressive form of breast cancer\u2014has been rejected by the panel that advises the U.K. health service on the grounds that it is too expensive.\n\nThe decision by the National Institute for Health and Care Excellence, known as NICE, reflects growing pressure on drug companies...", "article_metadata": {"article.template": "snippet", "article.created": "2014-08-08T11:39:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Kadcyla, one of Roche's most promising new drugs\u2014for women with an aggressive form of breast cancer\u2014has been rejected by the panel that advises the U.K. health service on the grounds it is too expensive.", "title": "U.K. Health Service Panel Rejects Roche Cancer Drug on Price Grounds", "image": {"src": "https://si.wsj.net/public/resources/images/BN-EA459_roche0_G_20140808075501.jpg", "alt": "The U.K.'s health service panel, NICE, rejects Roche cancer drug Kadcyla on price grounds", "identifier": "https://si.wsj.net/public/resources/images/BN-EA459_roche0_D_20140808075501.jpg"}, "creator": "@hesterplumridge", "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424052702303800604580079063906406060&headline=The%20U.K.%26apos%3Bs%20health%20service%20panel%2C%20NICE%2C%20rejects%20Roche%20cancer%20drug%20Kadcyla%20on%20price%20grounds&weburl=http://www.wsj.com/articles/SB10001424052702303800604580079063906406060"}}, "page.site.product": "WSJ", "keywords": "breast cancer drug,cancer drug,cancer drugs,drug approvals,kadcyla,nice,uk nice,Roche Holding,ROG.VX,National Institute for Health and Care Excellence,corporate,industrial news,breast cancer,cancer,political,general news,demographic health,health,medical conditions,women's health,pharmaceuticals,health care,life sciences,drugs,medication", "news_keywords": "breast cancer drug,cancer drug,cancer drugs,drug approvals,kadcyla,nice,uk nice,Roche Holding,ROG.VX,National Institute for Health and Care Excellence", "article.headline": "The U.K.'s health service panel, NICE, rejects Roche cancer drug Kadcyla on price grounds", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-EA459_roche0_E_20140808075501.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-EA459_roche0_D_20140808075501.jpg"}}, "description": "Kadcyla, one of Roche's most promising new drugs\u2014for women with an aggressive form of breast cancer\u2014has been rejected by the panel that advises the U.K. health service on the grounds it is too expensive.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424052702303800604580079063906406060&headline=The%20U.K.%26apos%3Bs%20health%20service%20panel%2C%20NICE%2C%20rejects%20Roche%20cancer%20drug%20Kadcyla%20on%20price%20grounds&weburl=http://www.wsj.com/articles/SB10001424052702303800604580079063906406060", "user.type": "nonsubscriber", "testkeys": "C", "article.page": "Business", "article.summary": "Kadcyla, one of Roche's most promising new drugs\u2014for women with an aggressive form of breast cancer\u2014has been rejected by the panel that advises the U.K. health service on the grounds it is too expensive.", "page.site": "wsj", "page.content.format": "responsive", "article.published": "2014-08-08T11:39:00.000Z", "dj.asn": "i-8b06", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "embed_count": 1, "image_count": 1, "word_count": 416, "internal_link_count": 6}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Kadcyla, one of Roche's most promising new drugs\u2014for women with an aggressive form of breast cancer\u2014has been rejected by the panel that advises the U.K. health service on the grounds it is too expensive.", "title": "U.K. Health Service Panel Rejects Roche Cancer Drug on Price Grounds", "url": "http://www.wsj.com/articles/u-k-health-service-panel-rejects-roche-cancer-drug-on-price-grounds-1407497976", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-EA459_roche0_G_20140808075501.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Hester Plumridge", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "U.K. Health Service Panel Rejects Roche Cancer Drug on Price Grounds", "article.type": "European Business News", "article.id": "SB10001424052702303800604580079063906406060", "user.exp": "default", "article.updated": "2014-08-08T11:39:00.000Z"}, "_id": "\"57477af36914bd0286fcfc1d\"", "article_summary": "The decision by the National Institute for Health and Care Excellence, known as NICE, reflects growing pressure on drug companies...\nLONDON\u2014One of Roche Holding AG's most promising new drugs\u2014for women with an aggressive form of breast cancer\u2014has been rejected by the panel that advises the U.K. health service on the grounds that it is too expensive."}